Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey, and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% (n= 103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Premedication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1–2 HSRs to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3–4 HSRs to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSRs in gynecologic cancer. Our study showed that HSRs in gynecologic cancer are common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSRs in gynecologic cancer was highlighted.
铂类和紫杉烷类化疗药物存在诱发超敏反应的风险，可能导致患者不得不转为疗效较差的替代治疗方案。通过脱敏疗法处理铂类和紫杉烷类超敏反应，可使患者按标准方案完成化疗。本研究旨在探讨妇科肿瘤患者对铂类和/或紫杉烷类化疗药物超敏反应的现行管理策略。我们针对妇科肿瘤医师和肿瘤内科医师开展了包含33个问题的在线横断面调查，共144名受访者完成问卷，其中133份纳入最终分析。参与者中妇科肿瘤医师占43.6%，肿瘤内科医师占33.8%，77.4%（n=103）直接参与化疗治疗工作。超过73%的参与者每年处理5例以上铂类/紫杉烷类超敏反应。对于铂类和紫杉烷类1-2级超敏反应，分别有84.8%和92.5%的参与者采用预处理后再次给药方案；而对于3-4级超敏反应，采用脱敏疗法的比例分别为49.4%和41.8%。多数参与者强烈强调需要规范妇科肿瘤铂类/紫杉烷类超敏反应的管理标准。本研究表明，妇科肿瘤化疗超敏反应虽常见，但临床处理方式存在差异且脱敏疗法使用率偏低，同时凸显了制定妇科肿瘤铂类/紫杉烷类诱发超敏反应管理指南的必要性。
肿瘤(癌症)患者之家